Erschienen in:
17.01.2023 | Original Article
Oncological monitoring after transanal total mesorectal excision (TaTME) for rectal neoplasia
verfasst von:
L. Sanchon, M. Bardaji, M. Labro, J. Curto, C. Soto, A. Puig, J. C. Pastor, C. Gómez, A. Osorio, C. Guariglia, S. Pardo, C. Vidal, P. Collera
Erschienen in:
Techniques in Coloproctology
|
Ausgabe 9/2023
Einloggen, um Zugang zu erhalten
Abstract
Background
The surgical treatment of choice for rectal neoplasia is total mesorectal excision (TME). The transanal approach enables a better approach in male and obese patients and/or those with a narrow pelvis and in patients with small tumors. Short-term results are comparable with those for laparoscopy or the open approach, but the medium- and long-term oncological data are sparse. The aim of the present study was to evaluate our early experience with transanal TME (TaTME).
Methods
This was a retrospective study conducted on patients who underwent TaTME at our center between August 2013 and April 2017 with a follow-up ≥ 3 years. Histopathology, complications, mortality, neoplastic recurrence and disease-free survival were analyzed.
Results
One hundred patients (68 men and 32 women,, median age 66.8 years [range 29.6–91.2 years]) were included. There were 67 T3 cases (67%) with 74 N0 cases (74%), the mesorectal quality was graded optimal for 87.6% and only 2 cases of radial margin involvement were detected (2%). The median follow-up period was 47.6 months (range 11.8–78.9 months). Eighteen cases of recurrence were diagnosed, of which 3 (3%) recurred locally with an average disease-free period of 43.1 months. Overall survival was 80% and mortality due to progression of disease was 13%.
Conclusions
TaTME is a safe surgical procedure with surgical, anatomopathological and oncological results at 3 years (medium-term) comparable with those for the laparoscopic and open approaches. Better monitoring is required with studies of the long-term functional and quality of life outcomes, i.e., at 5 or 10 years.